SOURCE: MusclePharm Corp.

April 10, 2013 08:00 ET

MusclePharm Sees Substantial Growth in International Markets

Company Targeting the UK, Brazil, Australia and the Middle East as Near Term Growth Territories -- Company Announces Endorsement Deal With International Rugby Star, Quade Cooper

DENVER, CO--(Marketwired - Apr 10, 2013) - MusclePharm Corporation (OTCQB: MSLP), a nutritional supplement company focused on active lifestyles, announced today it continues to see strengthening demand for its line of branded sports nutritional products in international markets.

During the year ended December 31, 2012, gross sales of MusclePharm products in international markets grew to approximately $27 million, an increase of over 550% as compared to gross sales of $4 million in 2011. In 2012, international sales accounted for approximately 35% of overall sales, up from 19% in 2011.

The Company views Brazil, the United Kingdom, Australia and the Middle East as key international markets where near term growth is expected to accelerate. As a result of MusclePharm's marketing and sponsorship partnership with the UFC, the Company's line of sports supplements has been a beneficiary of a number of very successful international UFC events.

Moreover, MusclePharm has recently increased its marketing efforts in Australia, a market the Company views as very promising. As part of that marketing campaign, MusclePharm has signed an endorsement deal with the Australian rugby superstar, Quade Cooper. As part of the relationship, Cooper will represent MusclePharm in a series of advertisements, media appearances, and social media outlets.

The 25-year old Quade is arguably the most exciting and electrifying rugby player in the world. Playing fly-half for the Queensland Reds, Quade delighted Reds fans in 2011 finishing the season with a record 228 points, besting the previous record of 171 points which he also set in 2010. Quade holds many of the Queensland Rugby records including most points scored (31) by a Reds player in a single Super Rugby match. Quade also boasts a strong social media following with 544,000 Twitter followers, 104,000 Facebook followers and 86,000 Instagram followers.

Commenting on the announcement, MusclePharm Founder & CEO Brad Pyatt stated, "It is encouraging to see how the popularity and awareness of the MusclePharm brand has increased throughout the international markets. Our relationship with UFC gives us a tremendous advantage in the international markets where UFC interest has taken off. We anticipate continued robust sales growth in international markets in 2013.

Pyatt continued, "Quade Cooper is a true international superstar in the world of rugby. His powerful body and overall ruggedness are representative of the MusclePharm brand. We purposefully timed the Cooper relationship with our accelerating international presence in the sports nutrition market."

This is the second professional athlete endorsement deal MusclePharm has recently announced. Last month, the Company announced a multi-year endorsement deal with the NFL San Francisco 49ers Super Bowl quarterback Colin Kaepernick.


MusclePharm is a healthy lifestyle company that develops and manufactures nutritional supplements which address active lifestyles, including muscle building, weight loss and maintaining general fitness through a daily nutritional supplement regimen. The products are formulated through a six-stage research process using the expertise of leading nutritional scientists. MusclePharm's products are sold to consumers in more than 90 countries and available in over 10,500 U.S. retail outlets, including Dick's Sporting Goods, GNC, Vitamin Shoppe and Vitamin World. MusclePharm products also are sold through more than 100 online channels globally, including, and MusclePharm also owns FitMiss™ (, a branded line of fitness supplements which is designed, dosed and formulated specifically for women with active lifestyles. For more information, please visit


This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K/A for the fiscal year ended December 31, 2011, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

Contact Information

  • MusclePharm Company Contact:

    John H. Bluher
    Telephone: 303-618-0902
    Email Contact

    MusclePharm Investor Contact:

    The Del Mar Consulting Group, Inc.
    Robert B. Prag
    Telephone: 858-794-9500
    Email: Email Contact


    Alex Partners, LLC
    Scott Wilfong
    Telephone: 425-242-0891
    Email: Email Contact